Evaluation of the Cerebrospinal Fluid Amyloid-�1-42/Amyloid-�1-40 Ratio Measured by Alpha-LISA to Distinguish Alzheimer's Disease from Other Dementia Disorders

The Alzheimer’s Association external quality control program for cerebrospinal fluid biomarkers

(2011) Niklas Mattsson et al.   Alzheimers & Dementia

High PIB Retention in Alzheimers Disease is an Early Event with Complex Relationship with CSF Biomarkers and Functional Parameters

(2010) A. Forsberg et al.   Current Alzheimer Research

CSF amyloid  38 as a novel diagnostic marker for dementia with Lewy bodies

(2010) E. Mulugeta et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Striatal Aβ peptide deposition mirrors dementia and differentiates DLB and PDD from other Parkinsonian syndromes

(2010) M.E. Kalaitzakis et al.   NEUROBIOLOGY OF DISEASE

AlphaLISA Immunoassay Platform— The “No-Wash” High-Throughput Alternative to ELISA

(2009) Martina Bielefeld-Sevigny   ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES

Cerebrospinal Fluid Total Tau Is Associated with Shorter Survival in Dementia with Lewy Bodies

(2009) Fredrik Boström et al.   DEMENTIA AND GERIATRIC COGNITIVE DISORDERS

Parkinson's disease dementia and dementia with Lewy bodies: different aspects of one entity

(2009) Dag Aarsland et al.   INTERNATIONAL PSYCHOGERIATRICS

CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment

(2009) Niklas Mattsson   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Combined CSF tau, p-tau181 and amyloid-β 38/40/42 for diagnosing Alzheimer’s disease

(2009) Volker Welge et al.   JOURNAL OF NEURAL TRANSMISSION

A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease

(2009) N A Verwey et al.   ANNALS OF CLINICAL BIOCHEMISTRY

Frequency and Case Identification of Dementia with Lewy Bodies Using the Revised Consensus Criteria

(2008) Dag Aarsland et al.   DEMENTIA AND GERIATRIC COGNITIVE DISORDERS